Telesis Bio Inc. has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. With more than twenty-eight years of experience as a Chief Financial Officer, Mr. Kullback has held a broad range of financial management and operational roles, primarily in mid-sized to large corporations, including multiple publicly held life-science companies.

Prior to joining Telesis Bio, Mr. Kullback served for five plus years as CFO of BioLegend, Inc., where he led the company's September 2021 sale to Revvity (formerly PerkinElmer). Before joining BioLegend in 2017, Mr. Kullback served as Chief Financial Officer of Lombard Medical, Inc. from 2014 to 2017, prior to its acquisition by MicroPort Scientific Corporation. Similar CFO appointments at other medical device and technology companies have resulted in a host of successful transactions involving debt, M&A buy-side, M&A sell-side, and public offerings.

Mr. Kullback earned both his MBA and bachelors degree from the State University of New York at Buffalo.